The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Clinical Roundup

Elahere demonstrates OS benefit in the phase III MIRASOL trial in FRα-positive, platinum-resistant ovarian cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

The phase III confirmatory MIRASOL trial (GOG 3045/ENGOT OV-55), which evaluated the safety and efficacy of Elahere (mirvetuximab soravtansine-gynx) in patients with folate receptor alpha-positive, platinum-resistant ovarian cancer who have received one to three prior lines of therapy, demonstrated statistically significant improvements in progression free survival, overall response rate, and overall survival compared to chemotherapy. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Positive topline results announced from phase I study of Lymphir + pembrolizumab in r/r gynecologic cancers

Citius Oncology announced positive topline results from a completed investigator‑initiated phase I clinical trial conducted by University of Pittsburgh investigators. This study evaluated the direct T-regulatory cell depletion activity of Lymphir (denileukin diftitox‑cxdl) in combination with the PD-1 immune checkpoint inhibitor pembrolizumab (Keytruda) in patients with recurrent or refractory gynecologic cancers, including ovarian and endometrial malignancies.
Drugs & Targets

FDA approves pembrolizumab with paclitaxel for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma

FDA approved pembrolizumab, as well as pembrolizumab and berahyaluronidase alfa-pmph in combination with paclitaxel, with or without bevacizumab, for adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumors express PD-L1 (CPS≥1) as determined by an FDA-authorized test, and who have received one or two prior systemic treatment regimens.
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account